Alan Meds vs Nova MD
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Nova MD
Best for patients comfortable with a 3-month plan commitment ($125/mo sema or $199/mo tirz) seeking the most competitive compounded pricing alongside an explicit microdose program and a multi-modality longevity menuStarting at $125/mo
Side-by-Side Comparison
| Feature | Alan Meds | Nova MD |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.2/10 |
| Starting Price | ✓$99/mo | $125/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.6 ★ /5 |
| Features | 5 features | ✓8 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | ✓ Yes |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Nova MD
Pros
- ✓Public, on-page pricing for all 4 SKUs (sema 1-mo, sema 3-mo, tirz 1-mo, tirz 3-mo) — material YMYL transparency advantage
- ✓$125/mo compounded semaglutide 3-month plan and $199/mo compounded tirzepatide 3-month plan are competitive with the cheapest decile of the US compounded telehealth market
- ✓$50 off first order on tirzepatide tier disclosed publicly
- ✓Microdose / low-dose program offered for both semaglutide and tirzepatide as a distinct SKU — uncommon explicit microdose offering
- ✓Multi-modality menu (Sermorelin, NAD+, Glutathione, Enclomiphene) for patients seeking longevity/strength alongside GLP-1
- ✓FSA/HSA eligibility disclosed (subject to plan specifics)
- ✓Same-day doctor review + cancel-anytime billing structure
Cons
- ✗Specific legal entity name + state of incorporation NOT publicly disclosed
- ✗Partner compounding pharmacy NOT publicly named (described only as 'accredited facilities' / 'partner pharmacy')
- ✗LegitScript certification status NOT confirmed on the home page (only generic 'Licensed US Providers' / 'US Pharmacies' claims)
- ✗Per-state availability NOT enumerated
- ✗Brand-name GLP-1 lineup (Wegovy/Zepbound/Mounjaro/Ozempic/Foundayo) NOT offered — compounded only
- ✗Site is a fully client-side React/Vite SPA — content is not visible to standard server-side scrapers / search engines unless rendered via headless browser, which is a soft SEO + transparency signal
- ✗Lab work + ongoing monitoring inclusion NOT clearly disclosed
- ✗Patient-served count ('1,241+') is a marketing claim with no third-party verification; treat as directional not authoritative
Our Verdict
Alan Meds edges out Nova MD with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Nova MD remains a solid alternative, especially if you're looking for patients comfortable with a 3-month plan commitment ($125/mo sema or $199/mo tirz) seeking the most competitive compounded pricing alongside an explicit microdose program and a multi-modality longevity menu.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.